glp 1 drugs vs metformin TrimRX Type 2 Diabetes Medications: Metformin,

There are three meta-analyses that examined whether GLP-1RA use was associated with increased risk for PDAC compared to the control arms (a combination of placebo and other diabetes medications)

The SELECT trial, which evaluated semaglutide 2.4 mg against placebo for cardiovascular outcomes in patients with overweight and obesity without type 2 diabetes, showed significant decreases in total cholesterol, LDL-C, and triglycerides and an increase in HDL-C at 39.8 months [48]

Digestive Support for GLP-1 Treatments: GLP-1 agonists frequently cause digestive side effects, with nausea occurring in 40% of cases, vomiting in 25%, and bowel disturbances in 23%, often leading to treatment discontinuation (Sun F et al., Diabetes Technology & Therapeutics , 2015)

[PubMed ID: 17244786]

Dual GLP-1/GIP agonists represent a significant new strategy for cardiovascular risk reduction, with ongoing research exploring triple GLP-1/GIP/glucagon agonists for even greater efficacy [68]